KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) EBIT Margin (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed EBIT Margin for 16 consecutive years, with 20.56% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 7945.0% to 20.56% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 33.58% through Dec 2025, down 2073.0% year-over-year, with the annual reading at 33.58% for FY2025, 2073.0% down from the prior year.
  • EBIT Margin for Q4 2025 was 20.56% at Halozyme Therapeutics, down from 61.51% in the prior quarter.
  • The five-year high for EBIT Margin was 68.19% in Q2 2021, with the low at 20.56% in Q4 2025.
  • Average EBIT Margin over 5 years is 47.27%, with a median of 52.06% recorded in 2024.
  • The sharpest move saw EBIT Margin surged 6970bps in 2021, then crashed -7945bps in 2025.
  • Over 5 years, EBIT Margin stood at 55.42% in 2021, then dropped by -26bps to 41.05% in 2022, then rose by 7bps to 43.92% in 2023, then surged by 34bps to 58.89% in 2024, then plummeted by -135bps to 20.56% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 20.56%, 61.51%, and 62.15% for Q4 2025, Q3 2025, and Q2 2025 respectively.